Good afternoon and welcome to the CytoSorbents Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the company's request. At this time, I'd like to turn the call over to our moderator, Eric Ribner. Please go ahead, Mr. Ribner. Thank you and good afternoon. Welcome to CytoSorbents Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call. Joining me today from the company are Dr. Phillip Chan, Chief Executive Officer, Vincent Capponi, President and Chief Operating Officer, Kathleen Bloch, Chief Financial Officer, Dr. Makis Deliargyris, Chief Medical Officer, Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe, Christopher Cramer, Senior Vice President of Business Development, and Dr. Irina Kulinets, Senior Vice President of Regulatory Affairs. Before I turn it over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today, and therefore we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates today as of March 14, 2024, and we assume no obligation to update these projections in the future as market conditions change. During today's call, we will have an overview presentation covering the operating and financial highlights for the fourth quarter and full year 2023 by Dr. Chan and Ms. Bloch. Following that presentation, we will open the line to your questions during the live Q&A session with the rest of the management team. Now it is my pleasure to turn the call over to Dr. Chan. Thank you very much, Eric. Thank you very much, Eric. Today I'd like to talk a little bit about our recent operational highlights. First of all, we're pleased to say that as of the end of 2023, we had more than 228,000 cumulative CytoSorb treatments delivered, which was up 17% from the end of 2022. Our European Union CE Mark for CytoSorb was extended under the Medical Devices Directive, MDD, to the earlier of either December 2028 or when we achieve EU Medical Device Regulation certification, also known as MDR, which effort is currently ongoing. We also entered into a new strategic partnership and temporary distribution agreement in India for CytoSorb with the publicly traded Indian pharmaceutical company Eris Lifesciences, following its definitive agreement with Biocon Biologics to acquire Biocon's Nephrology Branded Formulations Unit, and with it, Biocon's key leadership and field force of these businesses, including the personnel who are commercializing CytoSorb in India. Also of importance is our standalone hemoperfusion pump initiative. Our standalone pump initiative is expected to bring our next-generation blood purification capability to countries that do not have a strong dialysis infrastructure. We're expecting to launch our new PuriFi pump later this year, following the expiration of our distribution agreement with Nikkiso Europe GmbH for its PureAdjust pump in September of last year. And this is a picture of the pump. This is how it will look. It's very easy to use. We've had excellent feedback from users who have been beta testing this unit, and we're very excited to be able to get this out into the market, hopefully, in the very near future. Moving on to the STAR-T trial. The STAR-T randomized controlled trial, we're pleased to say, was selected for a breakout presentation at the American Association for Thoracic Surgery annual meeting being held April 27 through the 30th in Toronto, Canada. The AATS annual meeting is one of the most prestigious cardiothoracic surgery conferences in the world and attracts users, not only cardiac surgeons but perfusionists and a whole host of other healthcare workers who are involved in cardiothoracic surgery to learn about new innovations and clinical data in the area of cardiothoracic surgery. Following this presentation, we plan to have a subsequent analyst and investor day and provide a review of the data with investors and analysts by an esteemed thought leader panel. This will not be the same day as the AATS meeting presentation, but it will likely be either later that week or the following week. Based upon our additional analysis that we've done following our top-line data announcement in December, we plan to submit now for regulatory approval of DrugSorb-ATR to the U.S. FDA and Health Canada in the second half of 2024, with the idea of reducing the severity of bleeding in patients undergoing isolated CABG surgery on the blood thinner Brilinta. Here you see is a tentative estimated STAR-T timeline where the final data analysis is pending imminently. We expect to have the data presented at this late-breaking session at AATS in late April. Data from the STAR Registry, which is a real-world collection of data coming from Europe for using CytoSorb in the application to remove blood thinners, will an analysis of that registry, the third analysis, will be presented at the EuroPCR conference in Europe in May 2024. If everything goes well, we will be in a position to submit to FDA in the second half of this year. Based upon FDA timelines, 45 days after submission, the FDA will give formal notice, if appropriate, of acceptance. And from there, it's about an 8-10-month process based upon FDA published timelines to potential approval. In the meantime, we will also be preparing the Health Canada submission and will hopefully be able to get that out before the end of this year, setting up a timeline for the second half of 2025 to obtain potentially approval from FDA for DrugSorb-ATR and also approval from Health Canada as well. If things go well, we expect to begin commercialization shortly after receiving approval in the second half of 2025. We believe that focusing on our approval request on the isolated CABG population will not significantly change our U.S. and Canadian total addressable market opportunity, given that patients on Ticagrelor or needing isolated CABG represent the overwhelming majority facing this clinical need. On the next slide, you can see that the numbers haven't changed much from what has been in our investor presentation. There's about 65,000 patients on Brilinta needing emergent or urgent CABG surgery annually, and about $5,000 a device that represents about a $325 million initial U.S. and Canada total addressable market. We expect that the Brilinta market share will grow, given that DrugSorb-ATR would make Brilinta the only reversible P2Y12 platelet inhibitor on the market, and also because Brilinta goes off patent in 2024 this year, likely leading to a drop in prices, which has been the major advantage of Plavix, which is generic, in the United States market. Once that price differential goes away, we expect the superior drug Brilinta to gain market share, helping to potentially expand the total addressable market in the United States and Canada by twofold. Now, turning to our sales update, the press release, I think, goes over the sales highlights for 2023. However, I wanted to point out a few things. One is that core CytoSorb sales grew 10% year-over-year. Although that number is relatively modest, I think it masks some excellent performance that we have been seeing in certain of our sales divisions. As you recall, we have a hybrid sales model where we sell direct in Germany, we sell direct internationally in 14 other countries with our own direct sales force, and we sell in 60 other countries through our distributor and partner division. What we saw in 2023 was strong performance from our international direct division, again accounting for 14 countries, where they saw 27% sales growth to $6 million or roughly 19% of product sales for the year. This is important as we look to continue to diversify our revenue base to really account for the 75 countries around the world where we sell CytoSorb today. Distributor partner sales in the first three quarters of 2024 actually grew 18% versus the same period in 2022, not including U.S. distributor sales. However, because of the change that we made and the decision to let the Nikkiso PureAdjust hemoperfusion pump distribution agreement expire in favor of bringing our own pump to market, this impacted ordering from distributors and wound up with a delay in distributor orders flipping into 2024. Because of this, overall sales growth for the year was 9%, not including U.S. distributor sales, or 39% of product sales for the year. And finally, direct sales in Germany grew 3%. Although the markets have significantly improved in 2023, hospitals are still feeling the weight of the aftermath of COVID-19 in terms of staffing shortages, fewer ICU beds, fewer ICU patients, fewer high-revenue-generating procedures moving through the intensive care unit, but also a range of additional costs driven by inflation, including energy and staffing costs as well. However, we are seeing a significantly improved outlook for 2024, and we hope that this will begin a recovery in Germany. Germany represented 42% of our product sales last year. That said, we are currently tracking a proposal for healthcare reform of Germany's hospital system. In July 2023, Germany's federal and state governments issued a consensus white paper that could result in new laws that change how hospitals are funded. Government payments to hospitals would de-emphasize the DRG, also known as the Diagnosis-Related Group Lump Sum Payment System, that incentivizes revenue generation through more patients treated and procedures performed, and instead emphasize base payments focused on quality measures and appropriate patient care. This is expected to favor a shift of routine operations and procedures to outpatient centers, a consolidation of smaller hospitals into larger ones, and importantly, an increased focus of remaining hospitals on sicker patients, more complex operations such as cardiothoracic surgery and organ transplant, and on therapies that help reduce the severity of illness and help patients recover faster. Given that the goal of our therapies is to improve clinical outcomes while reducing the costs of critical care and cardiac surgery by controlling deadly inflammation and other life-threatening conditions, while reducing the need for expensive life support measures that keep patients in the hospital, we believe such reform may favor our business in the longer term. Hospital administrators expect such change will take careful planning and time, potentially even years, to implement, and we look to track these developments with interest. Now, many of you have seen this slide before where we talk about the extensive support of our technology by the U.S. government to the tune of about $50 million in grants and contracts and other non-dilutive funding. On the left-hand side, you see here three products that are actually being commercialized today. We typically focus on CytoSorb, and we don't really talk too much about ECOS-300CY or VetResQ, but today, I wanted to try to do that. In addition, on the right-hand side, our products under current development, and one of the products, HemoDefend-BGA, for the development of Universal Plasma, is a program which we've received $17 million for in DOD grant funding to bring this to market. I thought I'd spend a slide on each of these products just to give you a flavor of what we're doing today. ECOS-300CY is approved in the European Union for ex vivo organ perfusion and for solid organ transplant. Solid organ transplant is the main treatment option in advanced organ failure but is limited by the availability of suitable and healthy organs. Ex vivo organ perfusion, or otherwise known as EVOP, with temperature-controlled oxygenated nutrient-rich fluid or blood, is being increasingly used as an alternative to transporting the organ on ice to improve functioning of transplanted organs and to salvage substandard ones that would otherwise be discarded. However, it does not directly control inflammation within the organ that is often the core to the organ dysfunction that is seen perioperatively. ECOS-300CY is specifically EU-approved to reduce inflammatory mediators during EVOP. On the lower left-hand side here, you can see an ex vivo organ perfusion machine called the PerLife System by one of our partners, Aferetica, who's been one of the pioneers in this space. We work with them and provide a private-label cartridge called PerSorb that plugs right into their system. The goals and cited benefits of ECOS-300CY in early data are that it reduces inflammatory mediators, it helps to recondition poorly functioning organs that would normally be discarded, increasing the donor pool of organs, and in early data, in both pigs as well as in early human studies, has been shown to reduce rates of primary graft dysfunction, particularly in lung transplant, helping to improve clinical outcomes. On the next slide is VetResQ, which is essentially CytoSorb for companion animals. Now, the COVID pandemic has driven companion animal ownership, now with 45% of U.S. households owning a dog and 26% owning a cat, according to the American Veterinary Medical Association. Companion animals are prone to a wide variety of medical emergencies ranging from drug intoxication, heat stroke, infections such as leptospirosis, sepsis and septic shock, trauma, and others. VetResQ brings the power of CytoSorb to veterinary medicine with three sizes of cartridges intended to treat the full-size range of companion animals that you can see here. In 2023, we had a limited but successful launch of VetResQ to a number of regional veterinary centers, and in 2024, we'll debut our integrated all-in-one solution that includes a hemoperfusion pump for vets. Last but not least, HemoDefend-BGA, which holds the promise of universal plasma. HemoDefend-BGA was developed to create universal plasma, which is plasma that does not need blood typing and can be given off-the-shelf to anyone in need, regardless of blood type, by removing anti-A and anti-B antibodies that make plasma blood type specific. What you can see here on the right-hand side is the current status of plasma logistics today, where blood banks have to maintain pools of stores of type A, type B, type AB, and type O plasma. But universal plasma would simplify those logistics to then a simple unit called universal plasma that could be given off-the-shelf to a patient regardless of their blood type. Many applications of lifesaving plasma include trauma resuscitation, treatment of critically ill patients, and component purification, such as the isolation of clotting factors for hemophilia, for example, albumin for critical illness, and IVIG for autoimmune disease treatment and infectious disease. In the United States alone, more than 10,000 units of fresh-frozen plasma are administered daily, or 3.6 million units per year. And again, with more than $17 million in funding from the U.S. Department of Defense, CytoSorbents has successfully developed and demonstrated a prototype, HemoDefend-BGA adsorber, that removes anti-A and anti-B antibodies from human plasma with the goal of having our off-the-shelf, one-size-fits-all, blood type-independent universal plasma, provided that we can collaborate with a freeze-dried plasma provider, to have that universal freeze-dried plasma in every ambulance and emergency room around the world. This is a big opportunity, and we have now met recently with FDA in preliminary discussions with the goal of advancing HemoDefend-BGA to human clinical trials and commercialization. So with that, let me turn it over to Kathy to go back and cover financial highlights for 2023. Kathy? Thank you, Phil, and hello to everyone on the call. Today, I will discuss our Full Year and Fourth Quarter 2023 Financial Results, including revenue, gross margins. I will also be providing an update on our working capital and cash runway. Next slide, please. Total 2023 revenue, which includes both product sales and grant revenue, was approximately $36.3 million as compared to $34.7 million in 2022, which is an increase of approximately $1.6 million or 5%. CytoSorb product sales were $31 million in 2023 compared to $28.6 million in 2022, which is an increase of approximately $2.4 million or 9%. There was an increase in the average exchange rate of the euro to the U.S. dollar, and this favorably impacted 2023 CytoSorb product sales by approximately $780,000. Other non-CytoSorb product revenue was $70,000 for 2023 compared to $787,000 for 2022, this due to the discontinuation of orders from a customer who no longer required a specialized polymer. Our product gross margin was 72% in 2023, up from 70% in 2022. The company expects that gross margins will continue to improve into 2024 as we realize economies of scale at our new manufacturing facility. Finally, 2023 grant revenue was $5.3 million, which is approximately the same as 2022 grant revenue. Next slide, please. This next slide is our graph on which the blue bars represent our annual product sales for each year of 2017 to 2023. We know that 2020 and 2021 product sales were very favorably impacted because CytoSorb was used to treat COVID-19 patients. Of course, this usage ceased following the containment of the pandemic in subsequent years. Taking a look, though, at the orange trendline arrow, which tracks along the non-COVID revenue years, we see that 2022 and 2023 continues to show positive year-over-year growth in product sales. The post-COVID market has been challenging, particularly in Germany, for reasons already articulated by Phil in his comments. However, while gradual, we are seeing improvements in the marketplace, which we expect will bring more growth to our product sales for 2024 and into the future. I also want to just comment on the green line, which tracks our year-over-year gross margins, where we experienced a slight decline in 2022 when we began manufacturing at our new facility. This was a result of manufacturing inefficiencies. For example, we had to do test runs as we brought the new facility into full operation. Again, we do expect to see improvements in product gross margins in 2024. Next slide, please. Now, I'd just like to briefly review our fourth quarter 2023 results. Total revenue for the fourth quarter of 2023, which includes both product sales and grant revenue, decreased 8% to approximately $8.7 million compared to approximately $9.4 million in the fourth quarter of 2022. CytoSorb product sales were $7.3 million in the fourth quarter of 2023 compared to $7.4 million in the fourth quarter of 2022, a decrease of 1%. The increase in the average exchange rate of the euro to the U.S. dollar favorably impacted fourth quarter 2023 CytoSorb product sales by approximately $369,000. Other product revenue was $14,000 in 2023 compared to $246,000 in 2022, as we mentioned, due to the discontinuation of orders from a customer who required a specialized polymer. Grant revenue in the fourth quarter of 2023 was $1.3 million compared to $1.7 million in the fourth quarter of 2022. Next slide, please. As of December 31, 2023, we have $15.6 million in cash, which includes $1.5 million of restricted cash. This amount includes net proceeds of $9.8 million from our equity raised in December 2023 and approximately $4.5 million raised in 2023 utilizing our ATM facility. Conservation of cash is a corporate priority. We have adjusted our budget, and we've taken measures to reduce our quarterly cash burn in 2024. We have also instituted and continue to maintain tight controls over spending. These actions are expected to preserve our cash runway. We know that we will need to raise capital to support our ongoing operations in the future, and the company is actively pursuing other sources of capital, including less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. That concludes my remarks for today. At this time, I'm going to turn the call back over to Phil. Phil? Thank you, Kathy. So in summary, today, CytoSorb drives our growth. CytoSorb forms the company's foundation. It is EU-approved and sold around the world. It has generated more than $200 million in sales since launch. It is a high-margin razor blade business model with historical 80% blended product gross margins. And it has strong validation by customers, partners, and government agencies. We believe we can return to and potentially even exceed our historic compound annual growth rate of approximately 25%. We have previously discussed a number of macro trends in healthcare that favor our therapies, such as the aging population that is prone to critical illness, the use of blood thinners by millions of people worldwide to reduce the risk of heart attack and stroke, and the epidemic of chronic liver disease that afflicts one in every five people globally. Meanwhile, we have also discussed our numerous growth initiatives, like our standalone pump initiative with the pending launch of our own PuriFi machine, the impact that supportive data from STAR-T may have on the blood thinner opportunity worldwide, our global marketing agreement with Fresenius Medical Care, where CytoSorb is the featured solution for cytokine, bilirubin, and myoglobin removal on its critical care platforms worldwide, our new EU trademark of expanding the dimension of blood purification that highlights up to 50% of patients in the ICU where our therapies could be beneficial, and the relatively new applications with exciting recently published clinical data. Because of that, we believe that CytoSorb, which is designed to address the $20 billion-$30 billion worldwide total addressable market of major unmet medical needs in critical care cardiac surgery as well as liver and kidney disease, gives us a massive potential growth engine going forward. We believe this gives CytoSorb the potential upside of a biotechnology company with a lower risk profile of a high-margin medical device company with sales. But soon, should STAR-T be successful and DrugSorb-ATR achieve U.S. FDA and Health Canada regulatory approval, we intend to commercialize DrugSorb-ATR in both the United States and Canada, a potential second engine of growth working in tandem with CytoSorb to drive sales and ultimately profitability. At this stage, we believe our company represents an exceptional value proposition. So with that, operator, that ends our formal comments. Please open up the lines for questions. Thank you. As a reminder, if you do have a question, please press star 1 on your touch-tone phone. Please make sure your mute button is turned off to allow your signal to reach our equipment. Our first question comes from the line of Yuan Zhi with B. Riley Securities. Your line is open. Phil, thank you for taking our questions and congrats on the AATS breakout presentation opportunity. Just want to understand the timeline of this data release. So the conference will be in late April. Do you anticipate some abstract release before that? Thank you. Sure. Thanks, Yuan. Mike, do you want to take that? Sure. Thank you for the question. The data is part of the breakout session of clinical trials at the conference, and the acceptance goes together with the agreement of an embargo of releasing any of that information ahead of the conference. So the data will be released live during the AATS conference in Toronto, not ahead of that. Got it. And then, Phil, on the FDA device application, now with this STAR-T trial result, do you intend to submit 510(k) application or the pre-market authorization? Just want to check if there's a change of standard. Currently, we have not disclosed what the regulatory strategy will be, but suffice to say that we are currently working on that. But at the appropriate time, closer to submission, we'll make that publicly known. Got it. And maybe one last question from me. Just want to hear about the impact of this sales channel change. I'm curious, how long will this impact and the severity or recovery from this channel change in first half or second half this year? When you're talking about the channel change, are you talking about the relative distribution of sales from our three divisions? Yes. Yeah. Surprisingly, as it turns out, that the percentage contribution to product sales has remained relatively constant. What we have seen is that distributor sales have been growing in importance as that channel has gotten stronger and as those markets are being developed worldwide. So historically, Germany sales have been 50% of our sales base. It's currently, as of last year, 42%. And distributor sales, which have been historically 30%, are now 40%. And so we believe that if everything goes to plan, that those percentages should remain roughly the same. But it is predicated on Germany obviously recovering faster than we've seen it historically. But the good part is that we do see a change in the German market compared to a year ago. And maybe, Christian, you'd like to comment maybe on Germany and what you're seeing there. Yeah. Thank you, Phil. And thank you, Juan, for the question. So just to add some facts to what Phil said, yes, we see, obviously, a stabilization of the business in the more mature markets. So in more mature markets, I specifically say the Central European markets like Germany, Austria, Switzerland. But on the other hand, we see a much more pronounced path towards growth in the other direct markets and our distributor markets. And this is very much dependent on the stage of development. And I very much expect that these direct markets outside Germany, Austria, Switzerland, and the distributor markets come into a similar growth phase as we have seen in Germany two, three years ago. So that is one point. The other point is coming back to Germany, that as I said, we have seen the stabilization of the markets. But still, there's a lot of post-pandemic but also structural problems in the healthcare system. We are at the moment on a path to overcome this. And on top, we are having initiated or scheduled a number of initiatives over the year, of which two campaigns have started already. And we see already progress in these two campaigns. And so I think that on top of this stabilization I've talked about, we will see additional development if this is satisfying for you as an answer. Yuan. Thanks, Christian. Got it. Thanks for the additional color. That will be all from my end. Thank you. Our next question comes from the line of Thomas Kerr with Zacks Investment Research. Your line is open. Hello, everyone. Some of my questions were just answered. But can you give us more color on the India arrangement in terms of timeline and that sort of thing? And secondly, related to that, the slide said you're approved in the EU, obviously, and it's sold around the world. But is CytoSorb approved in other regions in Asia, South America, etc.? Yeah. Thank you. Kathy or Chris, would you like to comment on the Eris agreement? Or I can. I can only say that based on my conversations with the operations people in India, that the transition has gone very smoothly from Biocon to Eris. They've done a lot of retraining of the actual employees of Biocon who are knowledgeable of CytoSorb have transferred over to Eris. They've been retrained, and they are out and off to a successful beginning of the distribution partnership. Yeah. I think Biocon was an outstanding partner. Eris is a billion-dollar U.S. market cap publicly traded company, not as large as Biocon but kind of a specialty pharma company that has been very aggressive in the market and has been able to really take assets and grow them very impressively. We have a temporary agreement that has the same terms as the distribution agreement that we have with Biocon, with the exception of the expiration of the date of the agreement, which has been updated from September 2026 to now December 2020 to September 2026 from what was formerly December 2025 to basically give Eris some additional time in the market to get their feet wet with CytoSorb and to see what it can do. We expect to enter in good faith agreement to negotiate a new agreement with Eris. That will happen, hopefully, sometime in the near future. The second part of the question was, where else is CytoSorb sold right now? I was confused by one of the slides in the presentation. Yeah. So CytoSorb is sold, in fact, all over the world, with the notable exception of the United States, Japan, and China. But for example, we are in most of the, I think, if not all of the European Union countries. We're in many countries in Southeast Asia, for example, Singapore, Thailand, Vietnam, Hong Kong, South Korea, etc. We're in Russia. We're in many countries in the Middle East. We are in Australia, New Zealand. We are in India. And we are in many countries in Latin America. So in fact and we also have a footprint in South Africa as well. So not that much in Africa, notable exceptions of the U.S., Canada, Japan, and China. But otherwise, we have a fairly broad footprint around the world where we leverage our EU approval to be able to sell in these countries. Got it. Okay. Yeah. I wasn't quite sure about that. And on the quarterly burn rate for 2024, it used to be sort of in the $4 million-$4.5 million range. With all the cost savings initiatives, will it fall below that, do you think, in 2024 on a quarterly basis? Kathy, do you want to take that? Yes. So yes, you won't see the full impact of the cost-cutting measures in the first quarter of the year because there are sometimes some severance or other costs associated with the implementation. But you can expect our cash burn to be reduced to something around the order of $3 million a quarter in the last two quarters of the year. Okay. That is a little surprising because your stuff supports the DrugSorb-ATR development and that sort of stuff. That's still going to be covered, I'm assuming? We actually still have clinical trial costs in terms of winding down STAR- D, winding down STAR- T. We also have clinical programs ongoing such as the COSMOS Registry, our STAR Registry, and our PROCYSS randomized controlled trial that is running in Germany. There is still significant clinical spend that we are undertaking in 2024. But that being said, the burn will be dramatically lower than it was last year. Our goal is to, obviously, as Kathy mentioned in her presentation, cash conservation is key, right? I think we detailed many cost-cutting efforts, not just a 15% workforce reduction but cutting nonessential programs, particularly on the R&D side, as well as things even like a third year of salary freezes for executives, for example. So there's a lot of things across the board that we've been doing in this challenging financing environment. But we hope that with additional operational progress this year, that the value in our company begins to be unlocked and allows us to capitalize upon that. Got it. That makes sense. And last question, do you have a current share count? Because I don't see the 10-K filing yet on the SEC website or your website. Kathy, do you have that number? Yeah. Yeah. So our common shares outstanding right now are 54.2 million. Then in addition, we have options, warrants, and RSUs, which bring our fully diluted common shares outstanding to 67.9 million. I can send you that breakdown if it would help you, Tom. There are no further questions at this time. I would like to turn the call back to management for any additional or closing remarks. Well, thank you, everyone, for joining the call today. If you do have any other questions, please feel free to reach out to Kathy Bloch at kbloch, K-B-L-O-C-H, at cytosorbents.com. We will reply to your questions where possible. We look forward to the next quarterly call. Thank you, everyone, very much. Have a good night. Thank you. That concludes our conference for today. I'd like to thank everyone for their participation. You may now disconnect.